Results 161 to 170 of about 3,923 (195)
Some of the next articles are maybe not open access.

Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection

Expert Opinion on Drug Metabolism & Toxicology, 2018
Meropenem/vaborbactam (M/V) represents the first carbapenem and β-lactamase inhibitor combination approved for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a novel boronic acid, β-lactamase inhibitor with a high affinity for serine β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC ...
Rodrigo M, Burgos   +3 more
openaire   +2 more sources

A Brief Review of a New Antibiotic: Meropenem-vaborbactam

The Senior Care Pharmacist, 2019
Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire   +2 more sources

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho   +3 more
openaire   +2 more sources

Meropenem / Meropenem-vaborbactam

2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +2 more sources

Resistance to meropenem-vaborbactam in clinical isolates of Enterobacter roggenkampii without previous exposure to vaborbactam

Clinical Microbiology and Infection, 2022
Paula, Navarro-Carrera   +9 more
openaire   +2 more sources

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection

The Journal of Pediatric Pharmacology and Therapeutics
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Ugene, Sano   +3 more
openaire   +2 more sources

Meropenem – Vaborbactam

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +1 more source

Meropenem/vaborbactam

Reactions Weekly, 2020
openaire   +1 more source

Home - About - Disclaimer - Privacy